Genentech: Carmot Therapeutics
Carmot is currently conducting a multi-arm, double-blind, placebo-controlled Phase 1b clinical trial of CT-388. The primary endpoint of this trial is to evaluate the safety and tolerability of CT-388 in adult participants with overweight and obesity and in participants with T2D. It is designed to generate robust data to support dose and ...
Roche enters into a definitive merger agreement to acquire Carmot ...
2023年12月4日 · Carmot Therapeutics (Carmot) is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including obesity and diabetes. Based in Berkeley, California, the company employs ~70 people.
Carmot Therapeutics Raises $150 Million in Series E Equity …
BERKELEY, Calif., May 25, 2023 (GLOBE NEWSWIRE) — Carmot Therapeutics, Inc., a clinical-stage biotechnology company developing disease-modifying therapies for metabolic diseases, today announced a $150 million oversubscribed and up-sized Series E financing. The financing was led by Deep Track Capital.
BERKELEY, Calif., December 3, 2023 (GLOBE NEWSWIRE) — Carmot Therapeutics Inc. (Carmot), a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases including obesity and diabetes, today announced that it has entered into a definitive merger agreement for Roche to acquire Ca...
Our Approach | Carmot Therapeutics | Drug Discovery and …
Carmot’s clinical pipeline targets two main incretins, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP), both of which play significant roles in energy homeostasis.
Roche joins race for obesity drugs with $2.7 billion Carmot deal
2023年12月4日 · Roche agreed to take over unlisted obesity drug developer Carmot Therapeutics for $2.7 billion upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss...
Carmot Therapeutics Enters into Definitive Merger Agreement …
2023年12月4日 · Carmot’s clinical pipeline includes subcutaneous and oral incretins with best-in-class potential to treat obesity in patients with and without diabetes.
Roche makes obesity play with $2.7bn deal to buy Carmot
5 天之前 · Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapies for diabetes and...
Roche enters into a definitive merger agreement to acquire Carmot ...
Basel, 4 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive merger agreement to acquire Carmot Therapeutics, Inc. (“Carmot”), a privately owned US ...
Roche enters into a definitive merger agreement to acquire Carmot ...
2023年12月4日 · Carmot Therapeutics (Carmot) is a clinical-stage biotechnology company dedicated to developing life-changing therapeutics for people living with metabolic diseases, including obesity and...